Skip to main content
XORTX Therapeutics Inc. logo

XORTX Therapeutics Inc. — Investor Relations & Filings

Ticker · XRTX ISIN · CA98420Q2071 LEI · 254900RAT3XZPF9F9350 US Manufacturing
Open in API
Filings indexed 263 across all filing types
Latest filing 2025-01-21 Regulatory Filings
Country CA Canada
Listing US XRTX

About XORTX Therapeutics Inc.

https://www.xortx.com/

XORTX Therapeutics Inc. is a late-stage clinical biopharmaceutical company that develops and commercializes therapies for diseases associated with aberrant purine metabolism and high serum uric acid. The company's pipeline focuses on progressive kidney diseases, including Autosomal Dominant Polycystic Kidney Disease (ADPKD), Type 2 Diabetic Nephropathy (T2DN), and Acute Kidney Injury (AKI), as well as gout. Its lead program, XRx-008, is in development for the treatment of ADPKD.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a signature by the CEO and references an attached press release (Exhibit 99.1). The document length is short (1231 characters) and primarily serves as a notification of the press release filing rather than containing substantive financial data or detailed report content. There is no indication of full financial statements, management discussion, or detailed report content. Therefore, this document is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2025-01-21 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a signature by the CEO and references an attached press release (Exhibit 99.1). The document length is short (1227 characters) and primarily serves as a notification of the press release rather than containing substantive financial data or detailed report content. Form 6-K filings typically serve as regulatory filings for miscellaneous updates by foreign issuers. Therefore, this document fits best under Regulatory Filings (RNS).
2025-01-06 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a signature by the CEO and references an attached press release (Exhibit 99.1). The document length is short (1236 characters), and it primarily serves as a regulatory announcement of a press release rather than containing substantive financial data or detailed report content. There is no indication of full financial statements, audit information, or detailed management discussion. Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories.
2024-12-19 English
424B5
Capital/Financing Update Classification · 95% confidence The document is an Amendment No. 1 to a Prospectus Supplement filed pursuant to Rule 424(b)(5) under the Securities Act. It relates to an At The Market Offering Agreement and updates the terms of the offering, including the amount of common shares eligible to be sold. The document is a regulatory filing related to capital raising but is not a full financial report or earnings release. It is a specific type of capital/financing update document, as it amends the prospectus supplement for a securities offering. The document length is 4232 characters, which is relatively short but contains substantive amendment information rather than just an announcement of a report. Therefore, the best fitting category is Capital/Financing Update (CAP).
2024-12-13 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1244 characters), and it primarily serves as a regulatory filing to disclose a press release. According to the rules, such filings that do not contain full reports or detailed financial data should be classified as Regulatory Filings (RNS).
2024-12-12 English
Regulatory Filings 2024
Regulatory Filings
2024-11-26 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.